Lane Labs BeneFin Is Unapproved Drug - FDA Complaint
This article was originally published in The Tan Sheet
Executive Summary
FDA is seeking a permanent injunction against the sale of Lane Labs-USA's BeneFin, SkinAnswer and MGN-3 products, alleging they are "unapproved drugs" and "illegally promoted as treatments for cancer and other diseases."
You may also be interested in...
Lane Labs To Pay Consumer Restitution Under Permanent Injunction
The seven-year struggle between FDA and dietary supplement marketer Lane Labs-USA has formally concluded with a permanent injunction issued in Newark, N.J. federal court July 9
DSHEA Third-Party Literature Constraints Violate First Amendment – Lawsuit
The restrictions on third-party literature mandated by the Dietary Supplement Health & Education Act are a violation of the First Amendment's protection of free speech, supplement marketer American Longevity argues in a recent lawsuit against FDA filed in Southern California federal court
Lane Labs FTC Settlement To Fund National Cancer Institute Study
Lane Labs has been ordered by the Federal Trade Commission to contribute $450,000 to fund a National Cancer Institute clinical study on the effects of shark cartilage supplementation on cancer as part of a $1 mil. settlement of charges it made unsubstantiated cancer claims for its dietary supplements.